ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 940

IL1RN Variation Is Associated with Systemic Juvenile Idiopathic Arthritis and Predicts Non-Response to Anakinra Treatment

Emily Shuldiner1, Victoria Arthur1, Anne Hinks2, Patricia Woo3, Wendy Thomson2, Elaine F. Remmers4 and Michael J. Ombrello1, 1Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, 2Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, 3University College London, London, United Kingdom, 4Genetics and Genomics Branch, NIH, NIAMS, Bethesda, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Anakinra, Biomarkers, genetics and treatment, Systemic JIA

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses to treatment. Until recently genetic investigations of sJIA have consisted of candidate gene studies in small patient collections. These studies found only modest associations, yet these associations are regularly included in discussions of sJIA pathophysiology. Therefore, we examined the 11 reported sJIA candidate susceptibility loci (IL1A/B, GLI2, IL1RN/PSD4, IL1R2, IL10/20, IL6, MVK, CCR5, MIF, SLC26A2 and TAPBP) in the largest sJIA study population assembled to date.

Methods: Single nucleotide polymorphism (SNP) genotypes were extracted from the INCHARGE dataset, (771 sJIA, 6947 controls). Logistic regression was performed in each case-control stratum and association results were meta-analyzed. The effect of sJIA associated SNPs on gene expression was evaluated in silico in paired whole genome (WGS) and RNA sequencing (RNAseq) data from lymphoblastoid cell lines (LCL) of 373 European 1000 Genomes Project subjects. The relationship between sJIA associated SNPs and response to recombinant interleukin-1 (IL-1) receptor antagonist (anakinra) treatment was evaluated in 38 US patients for whom treatment response data were available.

Results: None of the 26 SNPs with previously reported sJIA associations demonstrated even nominal (p<0.05) association with sJIA in our study. We expanded the analysis to determine whether the 11 loci containing the 26 SNPs harbored any sJIA risk SNPs. We examined 5479 SNPs from the 11 candidate regions, among which 500 SNPs were independent (r2<0.5), defining the study’s significance threshold as p<1E-4. Association meta-analysis revealed only one significant association among the 11 candidate loci, the promoter region of IL1RN, where 3 SNPs in strong linkage disequilibrium showed a significant association with sJIA. Analysis of LCL data showed that the sJIA associated SNPs correlated with IL1RN expression, with an inverse correlation between sJIA risk and IL1RN expression. Importantly, the presence of homozygous IL1RN high expression alleles correlated strongly with non-response to anakinra (p=9.8E-4, OR 17.3 [2.8, 108.1]).

Conclusion: IL1RN was the only candidate locus associated with sJIA in our study. The sJIA associated SNPs are among the strongest known determinants of IL1RN and IL1RA levels, linking low expression with increased sJIA risk. Although high expression alleles were protective against sJIA, patients with 2 high expression alleles were significantly less likely to respond to anakinra treatment than those with 1 or 2 low expression alleles. Even though anakinra is well known to ameliorate or reduce inflammation in some sJIA patients, this is the first report to link sJIA risk and response to anakinra treatment with genetically determined capacity to produce IL1RN or IL1RA. These SNPs are the first potential biomarker(s) capable of prospectively guiding therapeutic decision making in sJIA.


Disclosure: E. Shuldiner, None; V. Arthur, None; A. Hinks, None; P. Woo, None; W. Thomson, None; E. F. Remmers, None; M. J. Ombrello, None.

To cite this abstract in AMA style:

Shuldiner E, Arthur V, Hinks A, Woo P, Thomson W, Remmers EF, Ombrello MJ. IL1RN Variation Is Associated with Systemic Juvenile Idiopathic Arthritis and Predicts Non-Response to Anakinra Treatment [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/il1rn-variation-is-associated-with-systemic-juvenile-idiopathic-arthritis-and-predicts-non-response-to-anakinra-treatment/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il1rn-variation-is-associated-with-systemic-juvenile-idiopathic-arthritis-and-predicts-non-response-to-anakinra-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology